期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 18, 期 -, 页码 1-8出版社
ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12037
关键词
Candida; Europe; framework; guideline development; recommendation
资金
- MSD (Schering-Plough)
- German Federal Ministry of Research and Education (BMBF) [01KN1106]
- Astellas
- Gilead Sciences
- Merck Sharp and Dohme
- Pfizer
- Schering Plough
- Astellas Pharma
- MSD
- Gilead
- Merck
- Schering
- National Institute of Health Research (NIHR)
- Medical Research Council
- National Institute for the Replacement
- Refinement and Reduction, of Animals in Research
- Bio-Merieux
- Cephalon
- Merck Sharp
- Dohme
- Astra Zeneca
- Novartis
- GSK
- Enzon
- Schering-Plough
- Abbott
- Nadirex International
- BMS
- Jansen
- bioMerieux
- Soria Melguizo SA
- Ferrer International
- European Union
- ALBAN program
- Spanish Agency for International Cooperation
- Spanish Ministry of Culture and Education
- Spanish Health Research Fund
- Instituto de Salud Carlos III
- Ramon Areces Foundation
- Mutua Madrilena Foundation
- National Institute for Health Research [CS/08/08/10] Funding Source: researchfish
Clin Microbiol Infect 2012; 18 (Suppl. 7): 18 Abstract The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) successfully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID task force (basically composed of members of the Societys Fungal Infection Study Group, EFISG) finalized the ESCMID diagnostic and management/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups were predefined, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplantation. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical intervention, which was graded by a score of AD for the Strength of a recommendation. The level of evidence received a score of IIII. The author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guidelines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据